Skip to content
GLP-1 Savers

Research & guides

Compounded vs Brand-Name GLP-1: Which Actually Saves You Money

Compare compounded GLP-1 offers with current brand-name cash-pay routes, insurance costs and dose terms to see which may cost less for your prescription.

By Grant Ashford, Founder & Pricing Editor
What's in this guide

The honest answer to "which is cheaper" is: it depends on your insurance, prescribed dose, cash-pay route and total fees. Brand-name and compounded GLP-1s may use the same active molecule — semaglutide or tirzepatide — but they are different products with different approval status and price terms. Compare the full cost of the treatment your clinician considers appropriate.

The two price worlds

Brand-name Wegovy and Zepbound are FDA-approved finished drugs12 with published U.S. list prices north of $1,000 a month before any coupon or coverage. Compounded semaglutide and tirzepatide are different, unapproved products. Their advertised figures mix starting doses, prepaid plans and different supply periods, so a median sticker price does not establish your ongoing bill. Confirm the dispensing pharmacy and the legal basis for your particular prescription. See each molecule priced separately on the current tirzepatide price ladder.

When brand-name is actually the cheaper path

If you have commercial insurance that covers Wegovy or Zepbound, or you qualify for the manufacturer savings cards, brand-name can drop to a low copay that beats any cash compounded price. In that case, paying cash for compounded would be overpaying. Check your formulary and the manufacturer savings program first — a covered brand prescription is often the single cheapest route when coverage exists. Just confirm you actually qualify, because eligibility is narrower than the ads suggest: see do GLP-1 savings cards actually lower the price?

When compounded wins on price

For the large group paying cash — no coverage, a high deductible, or a plan that excludes anti-obesity drugs — compare the current manufacturer self-pay offer with the compounded program's full ongoing charge. Some compounded offers are lower, but brand list prices above $1,000 are a poor cash comparison when manufacturer offers are available — see the full spread on the cheapest semaglutide ranking. This is the scenario most of our provider reviews are built for: cash-pay shoppers comparing price and program terms. A lower price does not establish that compounded treatment is clinically appropriate.

Keep the route and supply period on the page when you compare programs. RxSpan MD is a useful case because it sells compounded, oral and brand-name options at once, with its lowest advertised rates tied to a twelve-month plan. Henry Meds' formulation-specific pricing illustrates why an oral starting price should not be used as an injection quote. OrderlyMeds' starter-plan review shows why the introductory supply total and ongoing medication price need separate columns.

Our Peter MD review examines prepaid semaglutide packages whose estimated supply length needs clarification. A package total divided into a monthly illustration does not establish how long it will last at your prescribed dose.

The catch: compounded isn't the same regulatory product

Cheaper comes with a trade-off worth naming. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality the way brand-name drugs are3. A pharmacy license or certification does not establish that a particular compounded prescription meets the applicable legal requirements or is appropriate for you. Verify the dispensing pharmacy and the legal basis for the prescription, and read is cheap compounded GLP-1 safe? how to vet a low price before you buy on sticker alone.

Don't compare the intro rate

When you run the compounded-vs-brand math, use the compounded program's ongoing flat price, not a first-month teaser. A $99 intro that resets to $299 changes the whole calculation. We explain the pattern in how to spot a GLP-1 teaser-rate trap — it's the easiest way to think you're saving while quietly overpaying.

Two live examples of how the compounded side gets misread. The first is a promo dressed as a rate: The Edit's advertised $109 semaglutide is $100 off one order, and the standing price underneath it is $209. The second is worse, because there is nothing to compare at all — Lighter You keeps every price behind a login and advertises a headline figure that matches none of its five programs. Use a number you can still see in month three, or leave the program out of the comparison.

The bottom line

Covered by insurance? Check your actual brand copay and savings-card eligibility first. Paying cash? Compare the current manufacturer offer at your prescribed dose with the compounded program's ongoing medication and care charges, supply length and commitment. Neither route automatically costs less. Use the current manufacturer cash offers and our provider reviews to check the terms; discuss clinical suitability and any patient-specific compounding need with your prescriber.

One more brand-vs-brand wrinkle worth knowing

Brand pricing isn't even consistent across a single manufacturer's own products — see Mounjaro vs Zepbound: same drug, different price for a real example where the identical molecule, from the identical company, carries two different self-pay prices depending on which brand name it's sold under. And if you've seen ads for a newer, unapproved GLP-1 promising bigger numbers than either Wegovy or Zepbound, read retatrutide: is it available yet, and is it safe to buy right now? before you go looking for it — it isn't FDA-approved, and what's being sold under that name right now carries real risk.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.

For the tirzepatide side in detail, see what compounded tirzepatide actually costs per month.

Frequently asked questions

Is compounded GLP-1 the same as brand-name Wegovy or Zepbound?

It often contains the same active molecule, but compounded drugs are not FDA-approved and aren't reviewed for safety, effectiveness, or quality the way brand-name drugs are. The molecule may match; the regulatory status does not.

Is brand-name ever cheaper than compounded?

Yes. If your insurance covers Wegovy or Zepbound, or you qualify for manufacturer savings cards, the covered copay can beat any cash compounded price. Always check your formulary before assuming compounded is cheaper.

How much does cash-pay compounded GLP-1 cost?

Across the cash-pay programs we track it starts around $58 a month at the cheapest end and the median published price is near $170, varying by provider, molecule, dose tier and state.

References

  1. U.S. Food and Drug Administration (2021). FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 (Wegovy). FDA.gov. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
  2. U.S. Food and Drug Administration (2023). FDA Approves New Medication for Chronic Weight Management (Zepbound). FDA.gov. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  3. U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.